Noble Financial Has Bullish Forecast for Ocugen Q2 Earnings

Ocugen, Inc. (NASDAQ:OCGN) – Investment analysts at Noble Financial lifted their Q2 2026 EPS estimates for Ocugen in a research report issued to clients and investors on Wednesday, May 6th. Noble Financial analyst R. Leboyer now anticipates that the company will post earnings per share of ($0.05) for the quarter, up from their prior forecast of ($0.06). The consensus estimate for Ocugen’s current full-year earnings is ($0.22) per share. Noble Financial also issued estimates for Ocugen’s Q3 2026 earnings at ($0.05) EPS, Q4 2026 earnings at ($0.06) EPS and FY2026 earnings at ($0.22) EPS.

Other research analysts have also recently issued reports about the stock. Canaccord Genuity Group began coverage on shares of Ocugen in a research report on Tuesday, March 17th. They set a “buy” rating and a $12.00 price target on the stock. Wall Street Zen cut shares of Ocugen from a “hold” rating to a “sell” rating in a research report on Saturday, April 4th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Ocugen in a research report on Thursday, January 22nd. Oppenheimer began coverage on shares of Ocugen in a research report on Wednesday, March 11th. They set an “outperform” rating and a $10.00 price target on the stock. Finally, HC Wainwright increased their price target on shares of Ocugen from $7.00 to $10.00 and gave the company a “buy” rating in a research report on Wednesday, March 25th. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Ocugen currently has an average rating of “Moderate Buy” and a consensus price target of $9.75.

Ocugen Stock Down 1.0%

Shares of NASDAQ OCGN opened at $1.44 on Friday. Ocugen has a one year low of $0.64 and a one year high of $2.73. The company has a debt-to-equity ratio of 8.04, a current ratio of 1.06 and a quick ratio of 1.06. The firm’s 50 day simple moving average is $1.87 and its two-hundred day simple moving average is $1.58. The stock has a market capitalization of $487.47 million, a P/E ratio of -6.00 and a beta of 2.30.

Ocugen (NASDAQ:OCGN) last announced its earnings results on Tuesday, May 5th. The company reported ($0.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01). Ocugen had a negative net margin of 1,192.18% and a negative return on equity of 2,626.38%. The company had revenue of $1.53 million during the quarter, compared to analysts’ expectations of $0.42 million.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Cora Capital Advisors LLC grew its holdings in shares of Ocugen by 27.5% in the fourth quarter. Cora Capital Advisors LLC now owns 30,143 shares of the company’s stock worth $41,000 after purchasing an additional 6,500 shares during the last quarter. Jain Global LLC grew its holdings in shares of Ocugen by 7.2% in the fourth quarter. Jain Global LLC now owns 114,690 shares of the company’s stock worth $155,000 after purchasing an additional 7,686 shares during the last quarter. Lanham O Dell & Company Inc. grew its holdings in shares of Ocugen by 7.7% in the third quarter. Lanham O Dell & Company Inc. now owns 140,000 shares of the company’s stock worth $228,000 after purchasing an additional 10,000 shares during the last quarter. Procyon Advisors LLC grew its holdings in shares of Ocugen by 5.5% in the third quarter. Procyon Advisors LLC now owns 211,100 shares of the company’s stock worth $344,000 after purchasing an additional 11,000 shares during the last quarter. Finally, BNP Paribas Financial Markets grew its holdings in shares of Ocugen by 56.7% in the second quarter. BNP Paribas Financial Markets now owns 36,822 shares of the company’s stock worth $36,000 after purchasing an additional 13,326 shares during the last quarter. Institutional investors own 10.27% of the company’s stock.

About Ocugen

Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gene therapies to treat rare inherited retinal diseases, as well as vaccines designed to address unmet needs in infectious diseases. Headquartered in Malvern, Pennsylvania, the company applies its proprietary gene therapy platform to create novel treatments aimed at preserving and restoring vision, while leveraging strategic partnerships to broaden its vaccine pipeline.

In its gene therapy portfolio, Ocugen is advancing multiple programs targeting retinal disorders.